Skip to main content

Table 3 Gender examination of clinico-demographic factors for association with polypharmacy

From: Polypharmacy in patients with multiple sclerosis: a gender-specific analysis

  Female (N = 218) Male (N = 88)
p c OR (95% CI) p c OR (95% CI)
Age (years) < 0.001 1.075 (1.048–1.101) 0.013 1.053 (1.011–1.097)
School years* 0.288 0.879 (0.692–1.116) 0.803 0.954 (0.658–1.382)
Educational level* 0.012 0.635 (0.446–0.904) 0.402 0.809 (0.492–1.329)
Partnership* 0.082 1.852 (0.925–3.710) 0.524 1.399 (0.498–3.928)
Place of residence* 0.068 1.254 (0.983–1.599) 0.104 0.725 (0.493–1.068)
Number of children* 0.068 0.742 (0.539–1.022) 0.448 1.251 (0.702–2.229)
Number of siblings* 0.618 0.960 (0.819–1.126) 0.321 0.848 (0.612–1.175)
EDSS* < 0.001 1.653 (1.336–2.045) 0.005 1.454 (1.117–1.893)
Disease duration (years)* 0.993 1.000 (0.965–1.036) 0.179 0.959 (0.902–1.019)
Comorbidities* < 0.001 3.632 (1.885–6.996) < 0.001 6.213 (2.266–17.037)
Patient care* < 0.001 5.598 (2.857–10.970) < 0.001 11.820 (4.099–34.083)
  1. CI confidence interval, EDSS expanded disability status scale, N number of patients, OR odds ratio, p p value
  2. *Adjusted for age
  3. cUnivariable logistic regression